Comparing the Diagnostic Performance of [18F]PSMA-1007 With [68Ga]Ga-PSMA-11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer

PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate-specific membrane antigen (PSMA), a protein specific to prostate cells. [⁶⁸Ga]Ga-PSMA-11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [¹⁸F]PSMA-1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [¹⁸F]PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA-radiotracer is better than the other. Both ⁶⁸Ga and ¹⁸F-labeled PSMA-radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [¹⁸F]PSMA-1007 with that of [⁶⁸Ga]Ga-PSMA-11 in the detection of recurrent prostate cancer and determination of its stage. We found that [¹⁸F]PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11 showed similar diagnostic performance, with [¹⁸F]PSMA-1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.